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Although the sebaceous gland (SG) plays an impor-
tant role in skin function, the mechanisms regulating
SG differentiation and carcinoma formation are
poorly understood. We previously reported that
c-MYC overexpression stimulates SG differentiation.
We now demonstrate roles for the androgen receptor
(AR) and p53. MYC-induced SG differentiation was
reduced in mice lacking a functional AR. High levels
of MYC triggered a p53-dependent DNA damage
response, leading to accumulation of proliferative
SG progenitors and inhibition of AR signaling.
Conversely, testosterone treatment or p53 deletion
activated AR signaling and restored MYC-induced
differentiation. Poorly differentiated human seba-
ceous carcinomas exhibited high p53 and low AR
expression. Thus, the consequences of overactivat-
ing MYC in the SG depend on whether AR or p53 is
activated, as they form a regulatory axis controlling
proliferation and differentiation.INTRODUCTION
The sebaceous gland (SG) is part of the epidermis and produces
the sebum that lubricates the skin surface. SGs are often asso-
ciated with hair follicles (HFs), and loss of sebocyte function
can lead to scarring alopecia, indicating a dependence of HFs
on SGs (Sundberg et al., 2000). SG products also form the
protective lipid barrier of the skin and thus function in skin immu-
nity (Schneider and Paus, 2010), whereas specialized eyelid SGs
(meibomian glands) provide a lipid film to prevent drying of the
eye surface (McCulley and Shine, 2004). Sebaceous carci-
nomas, although rare, often recur locally, frequently metastasize,
and have high mortality (Buitrago and Joseph, 2008). There is
therefore considerable interest in elucidating SG biology.
Myc was first identified as the cellular homolog of the avian
myelocytomatosis viral oncogene (v-Myc) (Sheiness et al.,
1980) and originally designated c-Myc for cellular-Myc (HaywardCet al., 1981). MYC is a transcription factor that regulates sebo-
cyte differentiation (Arnold and Watt, 2001; Honeycutt and
Roop, 2004; Watt et al., 2008). K14MycER transgenic mice
provide an experimental model with which to study MYC-regu-
lated sebocyte differentiation. In these mice, human MYC is ex-
pressed under the control of the human keratin 14 (K14)
promoter as a fusion protein with a mutant mouse estrogen
receptor (ER) a ligand-binding domain. The MycER transgene
is constitutively expressed in the basal layer of the epidermis,
but MYCER protein (henceforth MYC) is only activated upon
topical activation of 4-hydroxytamoxifen (4OHT). Low levels of
MYC activation promote SG expansion and differentiation,
whereas high levels stimulate SG proliferation and inhibit differ-
entiation (Berta et al., 2010). MYC is often associated with
histone modifications marking active genes (Nascimento et al.,
2011; Rahl et al., 2010) and may therefore serve to amplify the
program of gene expression dictated by other transcription
factors. These observations led us to explore potential factors
that influence the outcome of MYC activation in the SG.
The Ar has been identified by chromatin immunoprecipitation
(ChIP) as a MYC target gene in mouse epidermis (Nascimento
et al., 2011), and MYC can promote androgen receptor (AR)
activity and ARmRNA expression in human prostate (Nadiminty
et al., 2012). In rats and humans, the AR is an early marker of
sebocyte differentiation (Bayer-Garner et al., 1999; Rosenfield
et al., 1998). In primary rat preputial sebocyte cultures, androgen
inhibits proliferation (Deplewski and Rosenfield, 1999). In
cultured human sebocytes, androgen can either promote or
inhibit proliferation, depending on the type of androgen and
the origin of the cells (Akamatsu et al., 1992). In vivo androgens
can promote growth and development of the human sebaceous
gland (Zouboulis, 2010), while poorly differentiated sebaceous
carcinomas have reduced AR expression (Bayer-Garner
et al., 1999). Nevertheless, testicular feminization (TFM) mice,
which have a spontaneous loss of function Ar mutation (Gaspar
et al., 1991), still form SGs (Markova et al., 2004), suggesting the
AR is dispensable for morphogenesis.
Another candidate modulator of MYC activity is p53. p53 is
mutated in two-thirds of sebaceous carcinomas (Kiyosaki
et al., 2010). Oncogenic levels of MYC activity promote p53
activation indirectly because of DNA damage (Hong et al.,ell Reports 3, 427–441, February 21, 2013 ª2013 The Authors 427
2006; Murphy et al., 2008; Pusapati et al., 2006). In human seba-
ceous carcinomas that retain p53 expression, elevated p53
protein levels correlate with worse prognostic outcome (Hasebe
et al., 1994; Hayashi et al., 1994; Izumi et al., 2008).
In the prostate, a mutually antagonistic relationship exists
between the AR and p53. p53 can inhibit AR gene expression
by direct association with the AR promoter (Alimirah et al.,
2007) and by inhibiting AR protein activity (Shenk et al., 2001).
Conversely, strong AR activity can inhibit p53 expression (Rokh-
lin et al., 2005) and p53 activity (Nantermet et al., 2004). Several
of the p53 mutants identified in sebaceous carcinoma (Kiyosaki
et al., 2010) are also found in prostate cancer and retain the
ability to impair AR signaling, despite being mutations in the
DNA-binding domain (Nesslinger et al., 2003).
Collectively, these observations prompted us to explore the
role of AR and p53 in modulating the consequences of MYC acti-
vation in the sebaceous gland.
RESULTS
Markers of SG Differentiation
The SG is a sac-like structure, comprising an undifferentiated,
proliferating, peripheral (basal) layer that gives rise to centrally
located differentiating sebocytes. As they accumulate lipids,
differentiating sebocytes increase in size (Montagna et al.,
1963; Rosenfield, 1989), eventually bursting to release their
contents into the sebaceous duct (SD), a thin, cornifying squa-
mous epithelium that connects the SG to the infundibulum of
the HF (Laurent et al., 1992; Schneider and Paus, 2010). Exper-
imental evidence from DNA label retaining cells (Reichelt et al.,
2004) and lineage tracing has established the existence of SG
stem cells (SCs) in the upper HF (Jensen et al., 2009; Snippert
et al., 2010). Their progeny travel around the basal layer to the
lower sebaceous tip before transiting internally and upward
toward the SD as they undergo terminal differentiation (Cui
et al., 2003; Petersson et al., 2011) (Figure 1N).
In telogen back skin of wild-type (WT) mice (Figures 1A–1M),
strong nuclear AR was observed in the lower SG, with weak
cytoplasmic and nuclear AR in the upper SG and elsewhere in
the epidermis (Figures 1A and 1B). Proliferative SG cells, marked
by Ki67 and proliferating cell nuclear antigen (PCNA) expression,
were enriched near the basal SG tip and had weak nuclear AR
(Figures 1C and 1D). Nuclear AR is indicative of active AR
signaling, and although the distribution of AR-positive cells in
the SG was the same in the males and females, males tended
to exhibit stronger nuclear staining than females (Figure 1B)
(Azzi et al., 2006). Skin is also a local source of androgens
(Chen et al., 2006, 2010). Antibody specificity was confirmed
by staining skin of AR-TFM mice, which lack functional ARs
(Figures S1N, S1O, and S1P).
Differentiating sebocytes expressed lipogenic enzymes, such
as fatty acid synthase (FASN) and peroxisome proliferator acti-
vated receptor g (PPARg) (Figures 1E and 1F). The largest sebo-
cytes, located next to the SD, had low AR activity, expressed the
Myc corepressor, B-lymphocyte induced maturation protein
(BLIMP1) (Figure 1G), and were weakly positive for involucrin
(IVL) (Lo Celso et al., 2008; Zouboulis et al., 1998) (Figure 1H).
Although BLIMP1 is reported to be a sebocyte progenitor marker428 Cell Reports 3, 427–441, February 21, 2013 ª2013 The Authors(Horsley et al., 2006), we only observed BLIMP1 expression in
differentiating sebocytes (Magnu´sdo´ttir et al., 2007) and in kera-
tinocytes of the SD, marked by IVL (Latham et al., 1989) (Fig-
ure 1H, see arrows). This is consistent with previous reports
that BLIMP1 is amarker of terminal differentiation in all epidermal
lineages (Chang et al., 2002; Lo Celso et al., 2008; Magnu´sdo´ttir
et al., 2007; Sellheyer and Krahl, 2010).
In wild-type mouse skin, MYC expression was higher in the in-
terfollicular epidermis (IFE) and SG than HFs (Reichelt et al.,
2004), consistent with the finding that MYC activation favors
differentiation along these lineages (Arnold andWatt, 2001; Hon-
eycutt and Roop, 2004) (Figure 1J). MYC was expressed by
differentiating, AR-positive sebocytes (detected with a 1:50 anti-
body dilution) (Figure 1K); however, the SG cells with highest
levels of MYC (detected with a 1:200 antibody dilution) were
basal, proliferating cells with low levels of AR (Figures 1L and
1M; Figure S1). Antibody specificity was confirmed on
K14MycER and epidermal Myc knockout mice (Figures S1B–
S1G, S1L, and S1M).
Figure 1N summarizes marker expression within the SG.
Proliferative basal cells express the highest levels of MYC,
whereas early differentiating sebocytes at the base of the SG
have high levels of nuclear AR. Mid-differentiated cells exhibit
high nuclear AR and express high levels of FASN and PPARg.
Late-stage differentiating sebocytes, in the upper part of the
gland, exhibit low levels of AR activity, low expression of IVL,
FASN, and PPARg, and are BLIMP1+ve.
Effect of MYC on AR Activity
We next examined the effect of MYC activation on proliferation,
differentiation, and AR activity in the epidermis. K14MycERmice
were treated once with a low (0.1 mg) or high (1.5 mg) dose of
4OHT or vehicle (acetone) and examined for up to 8 days (Fig-
ure S2A). Control K14MycER mice treated with acetone and
WT mice treated with 1.5 mg 4OHT were indistinguishable
from untreated WT mice (Figures 2A–2G) (Arnold and Watt,
2001; Berta et al., 2010). Although MYC activation is known to
promote IFE thickening and to cause hair follicle abnormalities
in K14MycER mice (Arnold and Watt, 2001), lineage tracing es-
tablished that there was no relocation of cells from the IFE to
the SG (data not shown).
Four days following low-dose 4OHT treatment, the SG of
K14MycER mice was enlarged and the differentiation compart-
ment expanded, as assessed by hematoxylin and eosin staining
(H&E) staining (Figure S2B) and AR and FASN expression
(Figures 2D–2I). On activation, the AR translocates to the
nucleus, and this provides a readout of AR activity in vivo. A
secondary readout is expression of FASN, which is an AR-
responsive gene (Schirra et al., 2005). Differentiation was quan-
tified (Figure 2C) by measuring the average cross-sectional area
of the SG differentiation compartment (Figure S2B).
The SGs of K14MycER mice treated with 0.1 mg 4OHT
enlarged by 4 days. This was not due to increased cell size (Fig-
ure 2J) but to an increased number of differentiating sebocytes
(Figure 2K), including AR-positive cells (bracket, Figure 2I), which
correlated with increased proliferation predominantly in basal
layer cells, but also occasionally in differentiated cells. By
8 days, low-dose 4OHT-treated SGs were hyperplastic
Figure 1. Expression of the AR and Other Markers in the SG
(A–M) Adult WT mouse telogen back skin labeled with antibodies to the markers indicated. (H) Arrows indicate a cell of either sebaceous duct (SD) or sebaceous
gland lineage (SG). (J–M) c-MYC antibody dilution is indicated. SG is outlined by dashed line in (F). Arrowheads indicate basal c-MYC +ve sebocytes. (I) Asterisks
indicate autofluorescent hair shaft.
(N) Schematic of SG showing undifferentiated sebocytes and early, mid, and late stages of terminal differentiation. Circular arrow indicates proliferating cells. HF,
hair follicle; SD, sebaceous duct; PC, progenitor cell.
Scale bars, 40 mm. See also Figure S1.
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(Figure 2C; Figures S4A and S4C), exhibiting weakened expres-
sion of FASN (Figures S4B and S4D) and increased proliferation
(Figures S4F and S4H).
In contrast to the effect of a low dose of 4OHT, by 4 days of
high-dose 4OHT treatment, the SGs of K14MycER mice were
filled with undifferentiated, immature sebocytes that frequently
lacked nuclear AR and exhibited reduced FASN expression, indi-
cating a collapse in AR signaling (Figures 2L and 2M). In some
cases cytoplasmic AR was also reduced (see Figure 6C). This
correlated with proliferative expansion of undifferentiated sebo-
cytes at the base of the gland (Figures 2L and 2M). The reduction
in the differentiation compartment (Figure 2C) was also observed
8 days after 4OHT treatment, the longest period for which mice
could be monitored (Berta et al., 2010). MYC activity remained
elevated at 4 and 7–8 days after one dose of 4OHT, as assessed
by qRT-PCR of Nucleolin (Figure 2P), an established MYC target
gene (Berta et al., 2010). In the IFE, formation of the cornified
envelope persisted (Figure 2L), indicating the negative effects
of high-dose MYC activation on differentiation were most
pronounced in the SG lineage.
Although MYC stimulates AR activity and AR expression in
prostate (Nadiminty et al., 2012), Ar mRNA levels in the skin of
K14MycER mice were not affected by low or high doses of
4OHT (Figures S2D, S2E, S2F, and S2G). In AR-luciferase assays
in immortalized human sebocytes, MYC repressed AR activity in
the presence of testosterone but stimulated activity in cells
treated with testosterone and the anti-androgen Casodex (Fig-
ure S2H), demonstrating MYC can regulate AR activity in
a context-dependent manner.
These data suggest that in response to a low dose of 4OHT
there is an accumulation of AR-positive differentiated sebocytes,
whereas the impairment in sebaceous differentiation upon high-
dose 4OHT treatment may reflect the inability of sebocytes to
exit the proliferative basal cell compartment and acquire AR
activity (Figure 2Q).
Effect of AR Activity on MYC-Induced SG Differentiation
To test the role of the AR in MYC-induced sebocyte differentia-
tion, K14MycER mice were crossed onto the AR-Shah x AR-
TFM strain background. Mice inheriting the AR-Shah reporter
allele have functional ARs (Shah et al., 2004). Mice inheriting
the AR-TFM mutation lack functional ARs (Gaspar et al., 1991).
Their SGs are morphologically normal (Figure 3A), although
sebum production was not assessed (Imperato-McGinley
et al., 1993). K14MycER AR-Shah mice exhibited a similar
response to low and high doses of 4OHT as the original
K14MycER mice, although the SGs of control K14MycERFigure 2. Effects of MYC Activation on SG Proliferation and Differentia
(A–Q) WT and K14MycER (Myc:) mouse telogen back skin was untreated, acet
sections were stained with H&E. (B, E, G, I, and M) Skin sections were stained w
sebocytes in (I). (C) Quantitation of SG differentiation compartment (average cro
iment described above. Red line represents average untreated WT measureme
individual differentiated sebocytes (cross-sectional area). (K) Average number o
sebocytes per SG. Red line represents untreated WT measurement. (O and P) q
summary of changes relative toWTSG of treatingK14MycERmice with low or high
cell number are represented by +, ++, or +++, according to the strength of the e
Three to ninemice were examined per condition. Error bars represent SEM#p < 0.
CAR-Shah/AR-TFM mice were slightly larger than original control
K14MycER mice.
Compared to K14MycER AR-Shahmice, K14MycER AR-TFM
mice showed a less pronounced induction of differentiation upon
low-dose 4OHT treatment (Figures 3A–3C). FASN expression
was reduced (Figure 3D), and there were increased numbers of
Ki67+ve cells within the SG (Figures 3E and 3F). Similar results
were observed when AR signaling in K14MycER mice was in-
hibited with high doses of Casodex (Figures S3I–S3K). As pre-
dicted from the block in differentiation, loss of AR did not affect
the response to high-dose 4OHT (Figures 3A–3C). Although AR
signaling is reported to regulate MYC protein stability (Bernard
et al., 2003), we did not observe a significant change inNucleolin
mRNA expression (Figure 3G). We conclude that AR activity is
required for efficientMYC-inducedSGdifferentiation (Figure 3H).
In contrast, genetic ablation of the Ar did not alter the IFE
response to MYC or MYC-induced changes in telogen HFs
(Arnold and Watt, 2001).
We next examined the effect of activating AR signaling
with testosterone. Daily application of 2 mg testosterone had
little effect on the number of differentiated sebocytes in WT
4OHT-treated and acetone-treated K14MycER mice of either
gender, confirming that testosterone did not act directly on the
MYCER fusion protein (Figure 4A). Testosterone did not enhance
SG differentiation in K14MycER mice treated with a low dose of
4OHT for 4 days, suggesting that AR activity was already
maximal in this condition (Figures S4G and S4H), although at
8 days SG hyperplasia was reduced (Figures S4E–S4H). In
contrast, daily application of 2 mg testosterone to high-dose-
treated K14MycER mice markedly stimulated differentiation
and increased the SG differentiation compartment to the same
extent as low-dose 4OHT (Figures 4A and 4D). Relocation of
the AR to the nucleus and increased FASN expression confirmed
testosterone restored AR activity (Figure 4B). Most sebocytes in
skin treated with high-dose 4OHT and testosterone were AR and
FASN+ve (Figures 4A and 4B), suggesting downregulation of AR
activity might be required for later stages of maturation (Fig-
ure 1N). This was confirmed by examining the effect of Casodex
on K14MycER mice treated with a low dose of 4OHT (Figures
S3A–S3H).
The AR-dependent action of testosterone was confirmed by
the competitive effect on SG differentiation of high doses of
Casodex (Figure 4G) and by the inability of testosterone to
rescue sebocyte differentiation in high-dose 4OHT K14MycER
AR-TFM mice (Figure 4H). Testosterone increased levels of
Nucleolin mRNA slightly, but the effect was not statistically
significant (Figure 4F).tion
one-treated (vehicle), or 4OHT-treated, as indicated. (A, D, F, H, and L) Skin
ith the antibodies shown. White bracket indicates expansion of AR-expressing
ss-sectional area occupied by differentiated sebocytes per SG) for the exper-
nt, and dashed red lines represent SEM. (J) Quantification of average size of
f differentiated sebocytes per SG cross-section. (N) Quantitation of Ki67+ve
RT-PCR of Ki67 and Nucleolin mRNA levels relative to Gapdh. (Q) Schematic
dose 4OHT. See Figure 1N for stages in sebocytes differentiation. Increases in
ffect. Reduction in cell number is represented by .
06, *p < 0.05, **p < 0.01, and ***p < 0.005. Scale bars 40 mm. See also Figure S2.
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Figure 3. Effect of Loss of AR Function during MYC Activation
(A–H) WT and K14MycERmice (Myc:) were crossed with AR-Shah or AR-TFMmice and treated as indicated. (A and B) Skin sections were stained with H&E. (C)
Quantitation of size of SG differentiation compartment. (D and E) Immunostaining (brown) for antibodies indicated. (F) Quantitation of Ki67+ve sebocytes. (G) qRT-
PCR ofNucleolinmRNA levels relative toGapdh. (H) Schematic summary of the effects of AR loss of function. See Figure 1N for stages in sebocyte differentiation.
Increases in cell number are represented by +, ++, or +++, according to the strength of the effect. Reduction in cell number is represented by .
Three to seven mice were examined per condition. Error bars represent SEM. *p < 0.05, **p < 0.01, and ***p < 0.005. Scale bars, 40 mm. See also Figure S3.
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The differentiation promoting effects of testosterone in
K14MycER mice treated with a high dose of 4OHT are summa-
rized in Figure 4I.
Role of p53 in MYC-Induced Sebocyte Differentiation
Oncogenic levels of MYC can activate p53 via DNA damage
(Hong et al., 2006; Murphy et al., 2008; Pusapati et al., 2006).
p53 can inhibit AR gene expression (Alimirah et al., 2007) and
activity (Shenk et al., 2001) and block lipogenesis (Hallenborg
et al., 2009). We therefore investigated whether p53 modulated
the K14MycER sebaceous gland phenotype.
MYC activation induced DNA damage throughout the
epidermis, as detected by g-H2AX expression (Pusapati et al.,
2006) (Figure 5A). When MYC was activated with high-dose
4OHT, accumulation of active p53 was observed with an anti-
body to nuclear p53 (Figures 5B and 5G). Antibody specificity
was confirmed on p53null mice (Figure S5A). However, the
number of cells expressing the apoptotic marker cleaved cas-
pase-3 was very low evenwhen high levels ofMYCwere induced
(Figure 5C). The induction of p53 was confirmed by qRT-PCR
(Figure 5D); in contrast, levels of total p63 and p73 were not
significantly changed (Figures 5E and 5F). Given that p53 was
induced within 4 days of MYC activation, it is likely to be wild-
type and not mutant.
When K14MycER mice were treated with 4OHT and testos-
terone, nuclear p53 protein (but not mRNA) levels were reduced
throughout the epidermis (Figures 5H–5J). p53 activity was
higher in K14MycER AR-TFM mice treated with a low dose of
4OHT than in K14MycER AR-Shah mice (Figures 5K and 5L),
confirming that AR functions to repress p53 activity (Nantermet
et al., 2004).
To examine whether p53 activation in K14MycERmice treated
with a high dose of 4OHT contributed to the inhibition of SG
differentiation, mice were crossed onto a p53null background.
In the SG, the effect was most profound and restored differenti-
ation, with increased numbers of cells expressing nuclear AR
and FASN, relative to mice that were heterozygous for p53
(Figures 6A–6C). IVL showed some restoration in expression,
but BLIMP1 expression was not restored (Figure S5B). Genetic
ablation of p53 partially reducedMYC-induced IFE hyperprolifer-
ative changes but did not alter MYC-induced changes in telogen
HFs (data not shown).
p53 deletion did not increaseAr (Figure 6D) orNucleolinmRNA
expression (Figure 6E) but increased MYC-dependent induction
of Fasn and Pparg (Figures 6F and 6G). Consistent with the stim-
ulation of differentiation, there was reduced expression of Ki67
(Figure 6H) and of Keratin 7 (K7), a sebaceous lineage marker
(Zouboulis et al., 1999) that is expressed in the SG basal layer
(Ju et al., 2011) (Figure 6I). Conversely, when p53 activation inFigure 4. Testosterone Modulation of AR Activity during MYC Activatio
(A–I) WT, K14MycER (Myc:), K14MycER AR-Shah, and K14MycER AR-TFM
(B and C) Skin sections were stained with the antibodies shown. (D) Quantitation
per SG. (F) qRT-PCR of Nucleolin (Nuc) mRNA levels relative to Gapdh. (G an
compartment size is shown. (I) Schematic summary of the effect of testosterone
sebocytes differentiation. Increases in cell number are represented by +, ++,
represented by .
Three to six mice were examined per condition. Error bars represent SEM. *p < 0.0
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tion of camptothecin (a topoisomerase inhibitor that causes DNA
breaks and activates p53 [Rudolf et al., 2011]) (Figures S5C–
S5F), AR activity and proliferation in the SG lineagewere reduced
resulting in a reduction in gland size (Figure S5F). Testosterone
coapplication partially antagonized the effects of camptothecin
on the SG (Figures S5C–S5F).
Wewere able to generate a singleK14MycER p53null AR-TFM
mouse. This mouse exhibited reduced SG differentiation and
enhanced proliferation compared to K14MycER p53null
controls, with proliferation persisting in FASN+ve sebocytes.
Sebocytes were also detected in the IFE (Figure 6J, see
arrowhead).
Collectively, these experiments suggest that p53 activation
resulting from DNA damage induced by high levels of MYC,
contributes to the inhibition of SG differentiation and disruption
of AR signaling (Figure 6K). Therefore, AR and p53 form an
axis of mutual antagonism controlling the outcome of MYC acti-
vation in the SG. For further details of all prior results, please refer
to the Extended Results.
AR and p53 Expression in Human Sebaceous Tumors
To place our observations into the context of human patho-phys-
iology, we examined expression of MYC, Ki67, AR, and p53 in
human sebaceous tumors. Human SGs differ from mouse back
skin SGs because they are larger and have a multilobed struc-
ture. In this regard the human SG resembles themurine preputial
gland (Figures 7A and 7B). In both human scalp SGs and mouse
preputial glands, we observed significant overlap in the expres-
sion of endogenous MYC and the AR, as well as MYC and the
proliferative Ki67 basal compartment. We also observed active
p53 in basal cells at low frequency (Figures 7A and 7B).
Differentiation status in tumors was assessed in H&E-stained
sections and correlated inversely with the number of Ki67+ve
cells, with one exception (Figure 7B). MYC was present in all
tumors but often at very low levels, and the level of MYC expres-
sion exhibited no correlation with proliferation, differentiation
status, or tumor type (Figure 7B).
Although p53 is often mutated in sebaceous carcinoma (Kiyo-
saki et al., 2010), many of these transcriptionally inactive muta-
tions can inhibit AR activity (Nesslinger et al., 2003). Tumors ex-
hibiting reduced differentiation had a higher proportion of
p53+ve sebocytes compared to AR+ve sebocytes, whereas
those with increased differentiation had an equal or higher
proportion of AR+ve sebocytes compared to p53+ve sebocytes.
Three specimens exhibited multiple neoplasms within a single
section, with distinct regions of adenoma (A) and carcinoma
(C). These confirmed that the differences between high and
low differentiation status tumors were not due to patient-specificn
mice were treated as indicated. (A) Skin sections were stained with H&E.
of the SG differentiation compartment. (E) Quantitation of Ki67+ve sebocytes
d H) Skin sections were stained with H&E. Quantitation of SG differentiation
on K14MycER mice treated with high-dose 4OHT. See Figure 1N for stages in
or +++, according to the strength of the effect. Reduction in cell number is
5, **p < 0.01, and ***p < 0.005. Scale bars, 40 mm. See also Figures S3 and S4.
(legend on next page)
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effects (Figures 7B and 7C). Our results suggest that mutual
antagonism of AR and p53 may contribute to progression of
sebaceous carcinoma.DISCUSSION
Our findings support a model whereby when MYC is overacti-
vated with a low dose of 4OHT, the AR inhibits proliferation
and stimulates the onset of differentiation. However, greater
MYC activity induces a p53 response as a result of DNA-
damage, consistent with previous observations (Pusapati et al.,
2006). The p53 response (increased nuclear p53 protein and its
downstream consequences) inhibits AR activity and without
the AR to trigger the onset of differentiation, cells continue prolif-
erating in response to MYC and accumulate as undifferentiated
sebocytes. The nonapoptotic p53 response could reflect the re-
ported ability of MYC to inhibit p53-mediated apoptosis (Cebal-
los et al., 2000).
The AR can promote or retard sebocyte proliferation, depend-
ing on androgen type and the body site from which sebocytes
are derived (Akamatsu et al., 1992). The phenotype of AR-TFM
mice highlights the antiproliferative role of the AR in murine
back skin following MYC activation but shows that the AR is
not required for SG differentiation during normal skin homeo-
stasis (Bayer-Garner et al., 1999; Rosenfield et al., 1998). In
rodent meibomian sebocytes, the AR functions early in differen-
tiation to initiate lipogenesis and lipid metabolism via transcrip-
tional regulation of genes, such as Fasn and Ppard (Schirra
et al., 2005, 2006). Placing the AR upstream of the lipogenic
program is consistent with our observations because peak AR
expression was observed just before the onset of differentiation
and then persisted during the first accumulation of lipids, marked
by FASN and PPARg. Downregulation of AR activity late in sebo-
cyte differentiation may play a role in the final stages of sebocyte
maturation because low doses of the anti-androgen Casodex
facilitated lipid accumulation (Figure S3D). The AR also appears
to have a role in repressing p53 activation (Figures 5H, 5I, 5K,
and 5L; Figures S4I and S4J and S5C–S5G), as previously re-
ported in prostate (Nantermet et al., 2004).
Loss of p53, like loss of AR, did not affect SG homeostasis,
that is, the normal balance between proliferation and differentia-
tion, although p53 is expressed in undifferentiated human and
mouse sebocytes (Figures 7A and 7B). p53 deletion restored
SG differentiation in high-dose 4OHT-treated K14MycER mice,
and this rescue was diminished in the absence of AR signaling,
highlighting the antagonistic effects of AR and p53. Additional
MYC-induced differentiation factors may be inhibited by p53,
such as PPARg (Figure 6G), which can bypass the requirement
for androgens in normal SG differentiation (Rosenfield et al.,
1999). Although p53 activation inK14MycERmice did not induce
apoptosis, epidermal Setd8 deletion triggers apoptotic p53 acti-Figure 5. Effect of MYC and AR Activation on p53 Expression, DNA Do
(A–L) WT and K14MycER (Myc:) mice were treated as indicated. (A) Skin sectio
(B, H, and K) Skin sections were labeled with antibodies to p53 (arrowheads indic
caspase 3. (D–F) qRT-PCR of mRNA levels relative to Gapdh. (G, I, and L) Quantit
PCR of p53 mRNA levels relative to Gapdh.
Three to nine mice were examined per condition. Error bars represent SEM. *p <
436 Cell Reports 3, 427–441, February 21, 2013 ª2013 The Authorsvation, resulting in loss of the IFE and SGs (Driskell et al., 2011a).
Increasing p53 activity with camptothecin (Figures S5E and S5G)
resulted in an apoptotic phenotype that was similar to the early
stages of epidermal Setd8 deletion (Driskell et al., 2011a),
demonstrating that different thresholds of p53 activation can
have distinct outcomes.
Our observation that AR and p53 are mutually antagonistic in
regulating MYC-induced sebocyte differentiation is relevant to
human sebaceous carcinoma. As in themousemodel, increased
numbers of p53-positive sebocytes correlated fewer AR-positive
sebocytes, reduced differentiation, and poor prognosis in the
tumors (Figure 7) (Bayer-Garner et al., 1999; Hasebe et al.,
1994; Hayashi et al., 1994; Izumi et al., 2008). MYCwas detected
in all the tumors we examined and did not correlate with Ki67
expression, consistent with a role of MYC in regulating both
proliferation and differentiation. Although in contrast to
K14MycER mice, p53 is often mutated in sebaceous carcinoma
(Kiyosaki et al., 2010) as a result of DNA damage, and these
mutations are still capable of inhibiting AR activity when tested
in prostate cells (Nesslinger et al., 2003). It is possible therefore
that within p53-positive sebaceous carcinomas, p53 accumula-
tion impairs AR signaling without inhibiting proliferation (Figures
5, 6, and 7). p53 could interfere posttranslationally with AR
activity by disrupting AR homodimerization and DNA binding
(Shenk et al., 2001). Alternatively, because AR and p53 protein
stability are both regulated by murine double minute 2 (MDM2),
AR downregulation in tumors could be due to activation of
MDM2 in response to increased p53 (Kulikov et al., 2010; Lin
et al., 2002). Finally, p53 could indirectly affect AR signaling by
reducing local androgen synthesis in the skin (Chen et al.,
2006, 2010; Hallenborg et al., 2009). The observation that p53
deletion confers resistance to spontaneous and chemically
induced epidermal papillomas and squamous cell carcinomas
(Greenhalgh et al., 1996) suggests that p53 activation also
influences differentiation in the interfollicular epidermis.
In conclusion, our study identifies an AR/p53 axis that deter-
mines the outcome of MYC overactivation in the SG. When
MYC activity is moderately elevated, the AR functions to prevent
p53 activation, terminate proliferation, and promote the onset of
differentiation. However, in response to high MYC activity, p53
can block AR signaling and thereby inhibit differentiation, leading
to expansion of undifferentiated sebocytes. Our observations
help to explain how MYC, an oncogene, can trigger SG differen-
tiation and how activation of p53 can facilitate proliferation of
undifferentiated cells in human sebaceous carcinomas via
downregulation of the AR.
EXPERIMENTAL PROCEDURES
Transgenic Mice
K14MycER transgenic mouse founder line 2184C.1 (Arnold and Watt, 2001)
was used for this study and maintained on a C57/Bl6 x CBA F1 background.uble Strand Breaks, and Apoptosis
ns were labeled with antibodies to g-H2AX with DAPI nuclear counterstain.
ate positive nuclei). (C) Skin sections were labeled with antibodies to cleaved
ation of p53+ve nuclei per unit area of skin (HF, SG, and overlying IFE). (J) qRT-
0.05, **p < 0.01. Scale bars, 40 mm.
Figure 6. Loss of p53 Function during MYC Activation
(A–K) Mice were treated as indicated. (A and J) Skin sections were stained with H&E. (B) Quantitation of SG differentiation compartment. (C and J) Skin sections
were stained with the antibodies shown. Arrowhead in (J) indicates sebocyte differentiation within the IFE. (D–I) qRT-PCR of mRNA levels relative to Gapdh.
(K) Schematic summary of effects of loss of p53 and combined loss of p53 and the AR. See Figure 1N for stages in sebocytes differentiation. Increases in cell
number are represented by +, ++, or +++, according to the strength of the effect. Reduction in cell number is represented by .
Scale bars, 40 mm. Error bars represent SEM. Three to five mice were examined per condition, except n = 1 for triple cross. NS, not significant. *p < 0.05,
**p < 0.01, ***p < 0.005. See also Figure S5.
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Figure 7. p53 and AR Expression in Human Sebaceous Tumors
(A) Mouse preputial gland sections were stained with H&E or the antibodies shown. Diagram on H&E indicates differentiation within each sebaceous lobe.
Arrowheads indicate p53+ve cells.
(B) Representative tumor sections are stained with H&E or the antibodies shown. Scale bars 40 mm.
(C) Summary of immunostaining and differentiation status of individual tumors. Staining was scored as follows.  negative, /+ almost entirely negative, +
to ++++ increasing proportion of positive cells, with ++++ indicating almost every cell positive.
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The other strains of mice used in crosses are described in the Extended Exper-
imental Procedures. Mice were treated once with 100 ml acetone or 0.1 or
1.5 mg 4OHT (Sigma-Aldrich H6278; Sigma-Aldrich, St. Louis, MO, USA) dis-
solved in 100 ml acetone. 4OHT was applied to clipped lower back skin, and
mice were analyzed 1–8 days later. In some experiments, mice additionally
received daily doses of 100 ml of acetone and/or 2 mg testosterone (Testos;
Sigma-Aldrich T1500) and/or 2, 4, or 8 mg Casodex (bicalutamide anti-
androgen; Sigma-Aldrich B9061) in 100 ml acetone. See Figure S2A for treat-
ment illustration and the Extended Experimental Procedures.
All experiments were performed on a minimum of three mice per condition,
with the exception of K14MycER p53null AR-TFM mice. Experiments were
subject to Cancer Research UK ethical review and performed under the terms
of a UK Government Home Office license.
Immunofluorescence, Immunohistochemistry, and Microscopy
Primary and secondary antibodies and labeling procedures are described in
the Extended Experimental Procedures and Table S1. Immunofluorescence
(IF) slides were counterstained with the nuclear dye DAPI. Immunohistochem-
istry slides were counterstained with hematoxylin.
qRT-PCR
RNA isolation, cDNA preparation, and qRT-PCR were performed using the Tri-
zol method as described previously (Driskell et al., 2011a) and described in
detail in the Extended Experimental Procedures.
Human Tissue
Samples were collected, diagnosed, and provided by H.G. and S.R.Q. or S.A.
and K.N. All samples were obtained with informed consent and processed for
research in accordance with the recommendations of the relevant local ethics
committees: CRUK Cambridge Research Institute (number 08/H0306/30),
German Medical Council, and/or the Japanese Ministry of Health, Labor,
and Welfare.
Quantitation and Statistics
Quantitation of Ki67, p53+ve cells, and the average cross-sectional area of the
SG differentiation compartment were determined from at least ten 10x images
of H&E-stained tissue sections per mouse. Only vertical sections of back skin
were quantitated. The SG differentiation compartment was identified in H&E
sections on the basis of differentiating sebocytes exhibiting pale and enlarged
cytoplasm from lipid accumulation. Examples of how measurements were
made are shown in Figure S2B. Statistical analysis was performed using the
unpaired Student’s t test.
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Supplemental Information includes Extended Results, Extended Experimental
Procedures, five figures, and one table and can be found with this article online
at http://dx.doi.org/10.1016/j.celrep.2013.01.013.
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